Page 49 - Haematologica - Vol. 105 n. 6 - June 2020

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3- internal tandem duplication: a position state- ment from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Ferrata Storti Foundation
Haematologica 2020 Ali Bazarbachi,1,2 Gesine Bug,3 Frederic Baron,4 Eolia Brissot,5 Fabio Ciceri,6 Iman Volume 105(6):1507-1516
Abou Dalle,1 Hartmut Döhner,7 Jordi Esteve,8 Yngvar Floisand,9,10 Sebastian Giebel,11 Maria Gilleece,12 Norbert-Claude Gorin,13 Elias Jabbour,14 Mahmoud Aljurf,15 Hagop Kantarjian,14 Mohamed Kharfan-Dabaja,16 Myriam Labopin,17,5 Francesco Lanza,18 Florent Malard,5 Zinaida Peric,19 Thomas Prebet,20 Farhad Ravandi,14 Annalisa Ruggeri,21 Jaime Sanz,22 Christoph Schmid,23 Roni Shouval,24 Alexandros Spyridonidis,25 Jurjen Versluis,26 Norbert Vey.27 Bipin N Savani,28 Arnon Nagler29 and Mohamad Mohty5
1Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; 2Department of Anatomy, Cell Biology, and Physiological Sciences, American University of Beirut, Beirut, Lebanon; 3Department of Medicine 2, Hematology and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany; 4GIGA-I3, University and CHU of Liège, Liège, Belgium; 5Sorbonne Universités, UPMC University of Paris 06, INSERM, Centre de Recherche Saint- Antoine (CRSA), Hematology Department, AP-HP, Saint Antoine Hospital, Paris, France; 6Vita-Salute San Raffaele University of Milan, Milan, Italy; Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; 7Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany; 8Hematology Department, Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcellona, Spain; 9Department of Hematology, Oslo University Hospital - Rikshospitalet, Oslo, Norway; 10Center for Cancer Cell Reprogramming, Institute for Cancer Research, Oslo University Hospital, Montebello, Oslo, Norway; 11Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Institute – Oncology Center, Gliwice Branch, Gliwice, Poland; 12Department of Haematology, Leeds Teaching Hospitals Trust, Leeds, UK; 13Department of Hematology and Cell Therapy, European Society for Blood and Marrow Transplantation, Paris Office, Hopital Saint-Antoine, Paris, France; 14Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 15Department of Hematology King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; 16Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program, Mayo Clinic, Jacksonville, FL, USA; 17Acute Leukemia Working Party, Paris Study Office, European Society for Blood and Marrow Transplantation, Paris, France; 18Romagna Transplant Network, Ravenna, Italy; 19University Hospital Center Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia; 20Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA; 21Department of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Roma, Italy; Eurocord, Hôpital Saint Louis, Paris, France; 22Hematology Department, Hospital Universitari i Politecnic La Fe. Instituto de Investigación Sanitaria La Fe, Valencia, CIBERONC, Instituto Carlos III, Madrid, Spain; 23Department of Hematology and Oncology, Augsburg University Hospital, Augsburg, Germany; 24Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 25BMT Unit, University of Patras, Patras, Greece; 26Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; 27Department of Hematology, Institut Paoli- Calmettes, Marseille, France; 28Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA and 29Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel Aviv University, Israel
ABSTRACT
The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% of patients with acute myeloid leukemia (AML). Because of the poor prognosis associated with FLT3-internal tandem duplication mutat- ed AML, allogeneic hematopoietic stem-cell transplantation (SCT) was commonly performed in first complete remission. Remarkable progress
Correspondence:
ALI BAZARBACHI,
bazarbac@aub.edu.lb
Received: November 19, 2019. Accepted: March 19, 2020. Pre-published: April 2, 2020
doi:10.3324/haematol.2019.243410
Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/105/6/1507
©2020 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
haematologica | 2020; 105(6)
1507
GUIDELINE ARTICLE